Cited 0 times in 
Cited 0 times in 
Secukinumab Efficacy Predictors in Korean Hidradenitis Suppurativa: A 48-Week Clinical Trial Analysis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Ha Nguyen, Ngoc | - |
| dc.contributor.author | Lee, Sang Gyu | - |
| dc.contributor.author | Ham, Seoyoon | - |
| dc.contributor.author | Lee, Ju Hee | - |
| dc.contributor.author | Lee, Young In | - |
| dc.date.accessioned | 2025-12-24T07:09:44Z | - |
| dc.date.available | 2025-12-24T07:09:44Z | - |
| dc.date.created | 2025-12-11 | - |
| dc.date.issued | 2025-10 | - |
| dc.identifier.issn | 2160-9381 | - |
| dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/209638 | - |
| dc.description.abstract | Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and draining tunnels commonly occurring in body folds. The IL-17A inhibitor, secukinumab, has shown efficacy in reducing HS lesions in clinical studies, but data on epidemiologic and patient-specific factors influencing response remain limited. Objectives: To assess how baseline disease severity, treatment initiation delay, and prior biologics exposure influence clinical response to secukinumab and patterns of antibiotic use. Materials and Methods: This 48-week real-world prospective trial enrolled 10 Korean patients with moderate-to-severe HS. Patients received secukinumab 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, then every two weeks. Outcomes included Hidradenitis Suppurativa Clinical Response (HiSCR), a 55% reduction in the International HS Severity Score System (IHS4-55), mean change in abscesses and inflammatory nodules, a >= 30% reduction in pain score on a numeric rating scale (NRS30), and duration of concomitant antibiotic use. Results: At week 48, 90% of patients achieved HiSCR, with 90% meeting the IHS4-55 threshold and 60% reaching the NRS30 criteria. Faster responses were recorded in subjects with Hurley stage II, treatment delays of <10 years, or no prior biologics use, although response rates equalized by week 48. All patients, particularly moderate cases, either discontinued or transitioned to monotherapy with systemic antibiotics. Conclusions: Secukinumab demonstrated efficacy in alleviating HS symptoms in moderate-to-severe cases. Patients with less severe disease, shorter treatment delays, and/or no prior biologic therapy exhibited more rapid initial responses. Additionally, the majority of patients experienced a significant duration of antibiotic cessation, underscoring the importance of early intervention. Future studies with larger populations are required to substantiate these findings. | - |
| dc.language | 영어 | - |
| dc.publisher | MATTIOLI 1885 | - |
| dc.relation.isPartOf | DERMATOLOGY PRACTICAL & CONCEPTUAL | - |
| dc.title | Secukinumab Efficacy Predictors in Korean Hidradenitis Suppurativa: A 48-Week Clinical Trial Analysis | - |
| dc.type | Article | - |
| dc.contributor.googleauthor | Ha Nguyen, Ngoc | - |
| dc.contributor.googleauthor | Lee, Sang Gyu | - |
| dc.contributor.googleauthor | Ham, Seoyoon | - |
| dc.contributor.googleauthor | Lee, Ju Hee | - |
| dc.contributor.googleauthor | Lee, Young In | - |
| dc.identifier.doi | 10.5826/dpc.1504a5933 | - |
| dc.identifier.pmid | 41236246 | - |
| dc.subject.keyword | Hidradenitis Suppurativa | - |
| dc.subject.keyword | Secukinumab | - |
| dc.subject.keyword | Korean Patients | - |
| dc.subject.keyword | Predictive Factors | - |
| dc.subject.keyword | IHS4-55 | - |
| dc.contributor.affiliatedAuthor | Ha Nguyen, Ngoc | - |
| dc.contributor.affiliatedAuthor | Lee, Sang Gyu | - |
| dc.contributor.affiliatedAuthor | Ham, Seoyoon | - |
| dc.contributor.affiliatedAuthor | Lee, Ju Hee | - |
| dc.contributor.affiliatedAuthor | Lee, Young In | - |
| dc.identifier.scopusid | 2-s2.0-105023102399 | - |
| dc.identifier.wosid | 001614960200029 | - |
| dc.citation.volume | 15 | - |
| dc.citation.number | 4 | - |
| dc.identifier.bibliographicCitation | DERMATOLOGY PRACTICAL & CONCEPTUAL, Vol.15(4), 2025-10 | - |
| dc.identifier.rimsid | 90464 | - |
| dc.type.rims | ART | - |
| dc.description.journalClass | 1 | - |
| dc.description.journalClass | 1 | - |
| dc.subject.keywordAuthor | Hidradenitis Suppurativa | - |
| dc.subject.keywordAuthor | Secukinumab | - |
| dc.subject.keywordAuthor | Korean Patients | - |
| dc.subject.keywordAuthor | Predictive Factors | - |
| dc.subject.keywordAuthor | IHS4-55 | - |
| dc.subject.keywordPlus | MULTICENTER | - |
| dc.subject.keywordPlus | ADALIMUMAB | - |
| dc.subject.keywordPlus | SUNSHINE | - |
| dc.subject.keywordPlus | SAFETY | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalWebOfScienceCategory | Dermatology | - |
| dc.relation.journalResearchArea | Dermatology | - |
| dc.identifier.articleno | e20255933 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.